163 related articles for article (PubMed ID: 25006730)
1. Spironolactone for heart failure with preserved ejection fraction.
Morawietz H; Bornstein SR
N Engl J Med; 2014 Jul; 371(2):181. PubMed ID: 25006730
[No Abstract] [Full Text] [Related]
2. Spironolactone for heart failure with preserved ejection fraction.
Kumar N; Garg N
N Engl J Med; 2014 Jul; 371(2):180. PubMed ID: 25006729
[No Abstract] [Full Text] [Related]
3. Spironolactone for heart failure with preserved ejection fraction.
Efthimiadis GK; Zegkos T; Karvounis H
N Engl J Med; 2014 Jul; 371(2):179-80. PubMed ID: 25006728
[No Abstract] [Full Text] [Related]
4. Spironolactone for heart failure with preserved ejection fraction.
Dalzell JR
N Engl J Med; 2014 Jul; 371(2):179. PubMed ID: 25006727
[No Abstract] [Full Text] [Related]
5. Spironolactone for heart failure with preserved ejection fraction.
Pfeffer MA; Pitt B; McKinlay SM
N Engl J Med; 2014 Jul; 371(2):181-2. PubMed ID: 25006726
[No Abstract] [Full Text] [Related]
6. Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction.
Kelly J; Granger CB
Ann Intern Med; 2014 Oct; 161(8):JC6. PubMed ID: 25329223
[No Abstract] [Full Text] [Related]
7. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
8. Effect of Mineralocorticoid Receptor Antagonists in Individuals With Heart Failure With Preserved Ejection Fraction: A Systematic Review.
Fernandes BP; Conceição LSR; Martins-Filho PRS; de Santana Motta DRM; Carvalho VO
J Card Fail; 2018 Sep; 24(9):618-621. PubMed ID: 30194985
[No Abstract] [Full Text] [Related]
9. Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?
Onarecker C
J Okla State Med Assoc; 2016 Sep; 109(9):437-8. PubMed ID: 29261854
[TBL] [Abstract][Full Text] [Related]
10. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
Mitter SS; Shah SJ
Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
12. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
[TBL] [Abstract][Full Text] [Related]
13. Application of the H
Myhre PL; Vaduganathan M; Claggett BL; Lam CSP; Desai AS; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Shah AM; Lewis EF; Rouleau J; Pitt B; Solomon SD
Eur J Heart Fail; 2019 Oct; 21(10):1288-1291. PubMed ID: 31332920
[TBL] [Abstract][Full Text] [Related]
14. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
[TBL] [Abstract][Full Text] [Related]
15. Spironolactone: diuretic or disease-modifying drug in heart failure with preserved ejection fraction?
Verbrugge FH; Damman K
Eur J Heart Fail; 2020 Sep; 22(9):1611-1614. PubMed ID: 32812323
[No Abstract] [Full Text] [Related]
16. Spironolactone, fibrosis and heart failure with preserved ejection fraction.
Reddy YNV; Sundaram V
Eur J Heart Fail; 2022 Sep; 24(9):1569-1572. PubMed ID: 35851716
[No Abstract] [Full Text] [Related]
17. Spironolactone an important addition to heart-failure treatment, study shows.
Miller JL
Am J Health Syst Pharm; 1999 Sep; 56(17):1695. PubMed ID: 10512491
[No Abstract] [Full Text] [Related]
18. Spironolactone in patients with heart failure.
Glick G
N Engl J Med; 2000 Jan; 342(2):133; author reply 133-4. PubMed ID: 10636752
[No Abstract] [Full Text] [Related]
19. Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial.
Petutschnigg J; Ferreira JP; Holzendorf V; Trippel TD; Hashemi D; Wachter R; Herrmann-Lingen C; Hasenfuß G; Zannad F; Pieske B; Edelmann F
Eur J Heart Fail; 2020 Mar; 22(3):559-561. PubMed ID: 31912594
[No Abstract] [Full Text] [Related]
20. Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction.
Bayoumi E; Lam PH; Dooley DJ; Singh S; Faselis C; Morgan CJ; Patel S; Sheriff HM; Mohammed SF; Palant CE; Pitt B; Fonarow GC; Ahmed A
Am J Med; 2019 Jan; 132(1):71-80.e1. PubMed ID: 30240686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
